115 related articles for article (PubMed ID: 28074551)
1. Detection of a clone-specific GATA1 mutation to monitor treatment response and involvement of a monozygotic twin in myeloid leukemia of Down syndrome.
Ali S; Ashraf K; Chen J; Hitzler JK
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28074551
[No Abstract] [Full Text] [Related]
2. Distinct GATA1 Point Mutations in Monozygotic Twins With Down Syndrome and Transient Abnormal Myelopoiesis From a Triplet Pregnancy: A Case Report and Review of Literature.
Yin L; Lovell MA; Wilson ML; Wei Q; Liang X
Am J Clin Pathol; 2016 Dec; 146(6):753-759. PubMed ID: 28028114
[TBL] [Abstract][Full Text] [Related]
3. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.
Alford KA; Reinhardt K; Garnett C; Norton A; Böhmer K; von Neuhoff C; Kolenova A; Marchi E; Klusmann JH; Roberts I; Hasle H; Reinhardt D; Vyas P;
Blood; 2011 Aug; 118(8):2222-38. PubMed ID: 21715302
[TBL] [Abstract][Full Text] [Related]
4. Analysis of GATA1 mutations and leukemogenesis in newborns with Down syndrome.
Queiroz LB; Lima BD; Mazzeu JF; Camargo R; Córdoba MS; Q Magalhães I; Martins-de-Sá C; Ferrari I
Genet Mol Res; 2013 Oct; 12(4):4630-8. PubMed ID: 24222239
[TBL] [Abstract][Full Text] [Related]
5. Myeloid leukemia in Down syndrome.
Khan I; Malinge S; Crispino J
Crit Rev Oncog; 2011; 16(1-2):25-36. PubMed ID: 22150305
[TBL] [Abstract][Full Text] [Related]
6. Acute leukemias in children with Down syndrome.
Zwaan MC; Reinhardt D; Hitzler J; Vyas P
Pediatr Clin North Am; 2008 Feb; 55(1):53-70, x. PubMed ID: 18242315
[TBL] [Abstract][Full Text] [Related]
7. Evolution of myeloid leukemia in children with Down syndrome.
Saida S
Int J Hematol; 2016 Apr; 103(4):365-72. PubMed ID: 26910243
[TBL] [Abstract][Full Text] [Related]
8. [Abnormal hematopoiesis in Down syndrome].
Ito E
Rinsho Ketsueki; 2014 Oct; 55(10):1738-47. PubMed ID: 25297735
[No Abstract] [Full Text] [Related]
9. GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.
Lum SH; Choong SS; Krishnan S; Mohamed Z; Ariffin H
Singapore Med J; 2016 Jun; 57(6):320-4. PubMed ID: 27353457
[TBL] [Abstract][Full Text] [Related]
10. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome.
Taga T; Saito AM; Kudo K; Tomizawa D; Terui K; Moritake H; Kinoshita A; Iwamoto S; Nakayama H; Takahashi H; Tawa A; Shimada A; Taki T; Kigasawa H; Koh K; Adachi S
Blood; 2012 Aug; 120(9):1810-5. PubMed ID: 22776818
[TBL] [Abstract][Full Text] [Related]
12. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.
Kanezaki R; Toki T; Terui K; Xu G; Wang R; Shimada A; Hama A; Kanegane H; Kawakami K; Endo M; Hasegawa D; Kogawa K; Adachi S; Ikeda Y; Iwamoto S; Taga T; Kosaka Y; Kojima S; Hayashi Y; Ito E
Blood; 2010 Nov; 116(22):4631-8. PubMed ID: 20729467
[TBL] [Abstract][Full Text] [Related]
13. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
Garnett C; Cruz Hernandez D; Vyas P
IUBMB Life; 2020 Jan; 72(1):119-130. PubMed ID: 31769932
[TBL] [Abstract][Full Text] [Related]
14. Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia.
Goemans BF; Noort S; Blink M; Wang YD; Peters STCJ; van Wouwe JP; Kaspers G; de Haas V; Kollen WJ; van der Velden VHJ; Gruber TA; Zwaan CM
Leukemia; 2021 Aug; 35(8):2403-2406. PubMed ID: 33483616
[No Abstract] [Full Text] [Related]
15. Down syndrome and GATA1-related transient leukemia.
Sandoval C; Pine SR
J Pediatr; 2007 Mar; 150(3):e34. PubMed ID: 17307526
[No Abstract] [Full Text] [Related]
16. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
17. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
18. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder.
Groet J; McElwaine S; Spinelli M; Rinaldi A; Burtscher I; Mulligan C; Mensah A; Cavani S; Dagna-Bricarelli F; Basso G; Cotter FE; Nizetic D
Lancet; 2003 May; 361(9369):1617-20. PubMed ID: 12747884
[TBL] [Abstract][Full Text] [Related]
19. Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.
Cruz Hernandez D; Metzner M; de Groot AP; Usukhbayar B; Elliott N; Roberts I; Vyas P
Blood; 2020 Sep; 136(12):1460-1465. PubMed ID: 32556129
[No Abstract] [Full Text] [Related]
20. Enigma of myeloid proliferation in Down syndrome.
Hasegawa D
Pediatr Int; 2019 Mar; 61(3):221. PubMed ID: 30916856
[No Abstract] [Full Text] [Related]
[Next] [New Search]
